Maxim Group expanded its equity research platform with the appointment of Caroline Palomeque as a SVP and a senior biotechnology analyst.
Prior to joining Maxim, Ms. Palomeque was a senior research analyst, covering the biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins, and coauthored several scientific papers for peer-reviewed academic journals.
“I am pleased to add someone with Caroline’s experience background to our healthcare platform,” Anthony Vendetti, executive managing director and head of equity research, said in a statement. “Healthcare is a core vertical at Maxim Group and biotechnology is an important component,” he added.